Tuberculosis in pregnancy

Best Pract Res Clin Obstet Gynaecol. 2022 Dec;85(Pt A):34-44. doi: 10.1016/j.bpobgyn.2022.07.006. Epub 2022 Jul 31.

Abstract

Due to COVID-19 pandemic, the latest progress of the End Tuberculosis (TB) Strategy was far from optimal and services for TB needs to be quickly restored. Pregnancy is a unique opportunity to screen and manage TB, and it is an essential step in TB eradication. Early diagnosis and treatment for active disease can reduce maternal and neonatal morbidities and mortality. The more widespread utilization of newer rapid molecular assays with drug-susceptibility testing has significantly shortened the diagnostic process for active TB disease. First-line anti-TB drugs are proven to be safe in pregnancy. Management of latent TB infection (LTBI) during pregnancy is controversial, but puerperium is a period of increased susceptibility to progress to active disease. Extrapulmonary TB (EPTB), multidrug-resistant TB (MDR-TB) and HIV co-infection remain significant issues surrounding TB management during pregnancy and often require input from a multidisciplinary team including TB experts.

Keywords: Anti-tuberculous drugs; Diagnostic tests; EPTB; HIV; Pregnancy; Tuberculosis.

Publication types

  • Review

MeSH terms

  • Antitubercular Agents / therapeutic use
  • COVID-19*
  • Female
  • HIV Infections* / complications
  • HIV Infections* / diagnosis
  • HIV Infections* / drug therapy
  • Humans
  • Infant, Newborn
  • Pandemics
  • Pregnancy
  • Tuberculosis* / diagnosis
  • Tuberculosis* / drug therapy
  • Tuberculosis* / epidemiology
  • Tuberculosis, Multidrug-Resistant* / diagnosis
  • Tuberculosis, Multidrug-Resistant* / drug therapy
  • Tuberculosis, Multidrug-Resistant* / epidemiology

Substances

  • Antitubercular Agents